Literature DB >> 6165832

Direct proof of the 5' to 3' transcriptional jump during reverse transcription of the avian retrovirus genome by DNA sequencing.

C A Omer, J T Parsons, A J Faras.   

Abstract

DNA sequence analysis of avian sarcoma virus in vitro-synthesized complementary DNA and in vivo-synthesized, molecularly cloned viral DNA provides unequivocal proof that only one copy of the terminally redundant viral RNA sequence is copied during reverse transcription.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6165832      PMCID： PMC171166          DOI： 10.1128/JVI.38.1.398-402.1981

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

1.  Avian myeloblastosis virus RNA is terminally redundant: implications for the mechanism of retrovirus replication.

Authors:  E Stoll; M A Billeter; A Palmenberg; C Weissmann
Journal:  Cell       Date:  1977-09       Impact factor: 41.582

2.  Nucleotide sequence that binds primer for DNA synthesis to the avian sarcoma virus genome.

Authors:  B Cordell; E Stavnezer; R Friedrich; J M Bishop; H M Goodman
Journal:  J Virol       Date:  1976-08       Impact factor: 5.103

3.  Nucleotide sequence of Rous sarcoma virus RNA at the initiation site of DNA synthesis: The 102nd nucleotide is U.

Authors:  J M Coffin; W A Haseltine
Journal:  J Mol Biol       Date:  1977-12-15       Impact factor: 5.469

4.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

5.  In vitro synthesis of infectious transforming DNA by the avian sarcoma virus reverse transcriptase.

Authors:  C H Clayman; E Mosharrafa; A J Faras
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

6.  Terminal redundancy and the origin of replication of Rous sarcoma virus RNA.

Authors:  J M Coffin; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

7.  Rous sarcoma virus genome is terminally redundant: the 3' sequence.

Authors:  D E Schwartz; P C Zamecnik; H L Weith
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

8.  Nucleotide sequence at the 5' terminus of the avian sarcoma virus genome.

Authors:  J Shine; A P Czernilofsky; R Friedrich; J M Bishop; H M Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

9.  Avian retrovirus RNA-directed DNA synthesis: transcription at the 5' terminus of the viral genome and the functional role for the viral terminal redundancy.

Authors:  M S Collett; A J Faras
Journal:  Virology       Date:  1978-05-15       Impact factor: 3.616

10.  RNase H hydrolysis of the 5' terminus of the avian sarcoma virus genome during reverse transcription.

Authors:  M S Collett; P Dierks; J T Parsons; A J Faras
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962
View more
  5 in total

1.  Activation of the cellular src gene by transducing retrovirus.

Authors:  S Ikawa; K Hagino-Yamagishi; S Kawai; T Yamamoto; K Toyoshima
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

2.  Evidence for involvement of an RNA primer in initiation of strong-stop plus DNA synthesis during reverse transcription in vitro.

Authors:  C A Omer; R Resnick; A J Faras
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

3.  Involvement of retrovirus reverse transcriptase-associated RNase H in the initiation of strong-stop (+) DNA synthesis and the generation of the long terminal repeat.

Authors:  R Resnick; C A Omer; A J Faras
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

4.  Products of reverse transcription in avian retrovirus analyzed by electron microscopy.

Authors:  R P Junghans; L R Boone; A M Skalka
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

5.  Structure of a replication intermediate in the synthesis of Rous sarcoma virus DNA in vivo.

Authors:  R Swanstrom; J M Bishop; H E Varmus
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.